On the Record · Incyte
Incyte acquisitions, on the record
The businesses Incyte bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
European operations of ARIAD Pharmaceuticals, Inc.Word for word“In June 2016, we acquired the European operations of ARIAD Pharmaceuticals, Inc., and obtained an exclusive license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries.” 10-K for 2023 | acquisition | In June 2016 | — |
Villaris Therapeutics, Inc.Word for word“In November 2022, we acquired Villaris Therapeutics, Inc., an asset-centric biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo.” 10-K for 2023 | acquisition | In November 2022 | — |
tafasitamab (MONJUVI/MINJUVI) rights from MorphoSysWord for word“For example, February 2024, we entered into a purchase agreement with MorphoSys under which we acquired rights to tafasitamab (MONJUVI/MINJUVI) that resulted in our holding exclusive global development and commercialization rights to tafasitamab.” 10-K for 2023 | acquisition | February 2024 | — |
Escient Pharmaceuticals, Inc.Word for word“As more fully described in Note 5 of Notes to the Consolidated Financial Statements, in May 2024, we acquired Escient Pharmaceuticals, Inc.” 10-K for 2024 | acquisition | May 2024 | — |
rights to tafasitamab (MONJUVI/MINJUVI) from MorphoSysWord for word“For example, February 2024, we entered into a purchase agreement with MorphoSys under which we acquired rights to tafasitamab (MONJUVI/MINJUVI) that resulted in our holding exclusive global development and commercialization rights to tafasitamab.” 10-K for 2024 | acquisition | February 2024 | — |
Escient Pharmaceutics, Inc. (Escient Pharmaceuticals, Inc.)Word for word“As described in Note 5 to the consolidated financial statements, on May 30, 2024, the Company acquired all of the outstanding shares of common stock of Escient Pharmaceuticals, Inc. (“Escient”), a clinical-stage drug development company, for $782.5 million in cash consideration.” 10-K for 2024 | acquisition | May 30, 2024 | $782.5 million in cash consideration |
MorphoSys AG and MorphoSys US Inc. (rights to tafasitamab)Word for word“For example, in February 2024 we entered into a purchase agreement with MorphoSys AG and MorphoSys US Inc. under which we acquired rights to tafasitamab (MONJUVI/MINJUVI) that resulted in our holding exclusive global development and commercialization rights to tafasitamab.” 10-K for 2025 | acquisition | February 2024 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $142.9 million | $155.7 million |
Deal filings since 2016
- 2024-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-08-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-06-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-04-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Incyte’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-10. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.